StockNews.com Initiates Coverage on BioLineRx (NASDAQ:BLRX)

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their price target on BioLineRx from $840.00 to $360.00 and set a “buy” rating for the company in a research note on Monday, November 25th.

BioLineRx Stock Performance

BioLineRx stock opened at $3.63 on Tuesday. The stock has a market cap of $7.26 million, a PE ratio of -0.41 and a beta of 1.41. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. BioLineRx has a 12-month low of $3.24 and a 12-month high of $57.60. The business’s 50-day moving average price is $7.26 and its two-hundred day moving average price is $17.55.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($2.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.20) by $0.40. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%. As a group, analysts expect that BioLineRx will post -5.8 earnings per share for the current fiscal year.

Institutional Trading of BioLineRx

A hedge fund recently raised its stake in BioLineRx stock. Atria Investments Inc boosted its holdings in shares of BioLineRx Ltd. (NASDAQ:BLRX) by 27.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 133,974 shares of the biotechnology company’s stock after acquiring an additional 29,193 shares during the quarter. Atria Investments Inc owned 0.17% of BioLineRx worth $72,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.